Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Indivior's Once-Monthly Buprenorphine Clears US FDA With Box Warning, REMS

Dec 02 2017

• By Brenda Sandburg

vialandmultiplesyringes_1200x675

Related Content

Buprenorphine Injectable Opioid Abuse Treatment: Will REMS Prevent Misuse?

Oct 29 2017

Indivior's Monthly Injectable Buprenorphine Wins Panel Backing; US FDA May Limit Dosage

Nov 01 2017

Braeburn's Buprenorphine Clears Advisory Committee, But US FDA Likely To Limit Dosage

Nov 02 2017

Related Companies

Indivior plc

Apple Tree Partners

Additional Topics

United States Regulation Approvals FDA BioPharmaceutical

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.